As expected there were correlations with alterations in translocation partner oncogenes and the GEP subgroups they define, for example, FGFR3 and WHSC1 alterations and the MS subgroup due to the t(4;14) rearrangement. The gene discussed is FGFR3; the disease is myeloid sarcoma.